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Abstract Osteoarthritis is the most common disease of joints
caused by degradation of articular cartilage and subchondral
bone. It is classified as primary form with unknown cause and
as secondary form with known etiology. Genetic and epige-
netic factors interact with environmental factors and contrib-
ute to the development of primary osteoarthritis. Thus far,
many polymorphisms associated with osteoarthritis have been
identified and recent studies also indicate the involvement of
epigenetic factors (e.g., telomere shortening) in the initiation
of this disorder. Accelerated shortening of telomeres was
detected in osteoarthritis and other age-related diseases.
Studies revealed that telomere length is severely reduced in
blood leukocytes and chondrocytes of patients with osteoar-
thritis, and this may contribute to the initiation and develop-
ment of osteoarthritis, whose major cause is still unknown.
Keywords Osteoarthritis . Telomere length . Telomere
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Osteoarthritis
Osteoarthritis is characterized by the degradation of articular
cartilage and subchondral bone, which results from an imbal-
ance between cartilage degeneration and regeneration process-
es. Osteoarthritis is classified as primary (idiopathic) of un-
known cause and secondary of known etiology. The current
state of knowledge leads to the conclusion that, in primary
osteoarthritis, genetic (Panoutsopoulou and Zeggini 2013) and
epigenetic factors (Yamasaki et al. 2009; Li et al. 2012a, b)
interact with environmental factors and contribute to osteoar-
thritis development and its further progression.
The most common causes of the secondary form are joint
inflammation, obesity, post-traumatic changes, congenital de-
formation, joint dysplasias, diseases of the joints in childhood,
metabolic disorders, hormonal imbalance, abnormal joint de-
velopment, calcium crystal deposition, neuropathy, acromeg-
aly, hemophilia, and a predisposition to systemic diseases
(Rosenthal 2006; Buckwalter and Martin 2006).
Osteoarthritis most frequently affects the hips, knees, spine,
and joints of the hand (Dieppe and Lohmander 2005). The
symptoms of the disease increase with age, and include main-
ly joint pain, contractures of the surrounding muscles, and
gradual reduction in the range of motion. Radiological fea-
tures of osteoarthritis are joint space narrowing, subchondral
bone sclerosis, osteophytes, or bone cysts. Osteoarthritis is
one of the diseases causing the most serious disabilities world-
wide and generates enormous costs both directly (e.g., medi-
cal and non-medical costs) and indirectly (e.g., reduction in
labor productivity) (March and Bachmeier 1997). The results
of the Global Burden of Disease Study 2010 published in The
Lancet (2012) show that 250,785,000 people are affected by
knee osteoarthritis, which accounts for 83 % of the total
osteoarthritis cases (Vos et al. 2012). Treatment of patients
affected by osteoarthritis depends on the stage of diagnosis
and is highly individualized. In mild osteoarthritis, the first
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approach is non-pharmacological treatment (e.g., education,
exercise, diet, and physiotherapy) or intra-articular steroids or
hyaluronic acid injections. More severe osteoarthritis may be
treated pharmacologically with non-steroidal anti-inflamma-
tory drugs (NSAIDs) or opioids. At the late stage of osteoar-
thritis, surgery involving the osteotomy or total joint replace-
ment is the most common approach (Hunter and Felson 2006).
Since osteoarthritis is considered a growing problem, particu-
larly in the aging populations, many new treatments are cur-
rently being tested, including a biological therapy based on
platelet-rich plasma, intra-articular cell therapy, or nanotech-
nology (Anitua et al. 2013; Peeters et al. 2013; Gu et al. 2013).
Aging cartilage
In healthy cartilage, under normal conditions, cell divisions
are practically minimal and aging is manifested as a slight
decrease in the number of chondrocytes and thinning of the
cartilage layers (Aurich et al. 2002; Horton et al. 2006; Li et al.
2013). Hudelmaier et al. (2001) conducted a study to assess
the changes in the morphology of cartilage in the aging
process. For the evaluation of the cartilage, they used mag-
netic resonance imaging, which revealed that cartilage in
elderly patients, not affected by diseases and injuries within
joints, is thinner than in young patients. They also showed that
the reduction in cartilage thickness depends on gender and
joint compartment. Changes that occur with age in cartilage
predispose to joint injuries (Ding et al. 2005). Aurich et al.
(2002) compared the cartilage for the content of main com-
ponents of an extracellular matrix in young and aged donors.
There were no significant differences in the content of type II
collagen, glycosaminoglycans, and aggrecans between the
two studied groups. In contrast, chondrocytes in the osteoar-
thritic cartilage lose their ability to synthesize matrix compo-
nents and begin to synthesize proteins, which contribute to
degradation of the extracellular matrix (Loeser 2009). Del
Carlo and Loeser (2003) compared a response to oxidative
stress of chondrocytes isolated from elderly and young indi-
viduals. The results indicated that chondrocytes isolated from
the cartilage of the elderly are more susceptible to oxidative
stress and, consequently, to the reactive oxygen species-
associated cell death.
Telomeres
Recent studies show that telomere shortening may became a
significant epigenetic factor contributing to osteoarthritis. We
analyzed the current literature about telomeres and reported
telomere shortening in the blood and cartilage of patients with
different forms of osteoarthritis. Telomeres are located at the
ends of chromosomes. Human cells consist of a repeated
telomeric sequence (TTAGGG)n, which is 5–15-kb long.
Telomeres are necessary to maintain chromosome stability
and prevent chromosome end fusion (Meyne et al. 1989;
Tamayo et al. 2010). After each replication cycle, they are
shortened by 50–150 bp (Harley et al. 1990; Counter et al.
1992). Enzyme telomerase, which is a large ribonucleoprotein
complex, is able to reconstruct lost telomeric repeats and is
active in stem cells and germ cells (Gilley et al. 2008). The
telomerase complex is comprised of reverse transcriptase
(TERT), RNA template for the synthesis of telomeric repeats,
and the dyskerin protein complex (Chen et al. 2000; Bailey
and Murnane 2006; Podlevsky et al. 2008). In most somatic
cells of the human body, the lack of telomerase activity leads
to the telomeres shortening, which is closely associated with
the aging process and development of age-related diseases
(Gilley et al. 2008). Besides telomerase, there are many im-
portant factors that play a role in the protection of chromo-
some ends. In human cells, there is a shelterin complex,
consisting of six proteins. This complex includes telomeric
repeat binding factors (TRF1 and TRF2), POT1 protein, and
three linker proteins that allow the formation of a protein
complex (TIN2, TPP1, and Rap1) (de Lange 2005; Martinez
et al. 2010; Lu et al. 2013). TRFs function as an inhibitor of
telomere elongation; POT1 protein binds to TTAGGG re-
peats, controls telomeres elongation by telomerase, and pro-
tects their ends. TIN2 protein is a central part of the shelterin
complex and interacts with TPP1, TRF1, and TRF2. TPP1
protein interacts with the telomerase and directs it to the
telomeres; Rap1 acts as a regulator of telomere function and
of transcription (de Lange 2005; Martinez et al. 2010; Lu et al.
2013). Heterochromatin protein 1γ (HP1γ) binds to TIN2
protein and is involved in maintaining telomere cohesion
(Canudas et al. 2011). The shelterin complex mediates the
formation of telomere loops (T-loop) stabilized by smaller D-
loops and, together, protect the telomere ends from fusing
(Kong et al. 2013). SIRT6 protein plays a very important role
in telomere protection and genome stability (Sharma et al.
2013). These investigators also reported that, in an SIRT6
mouse knockout model, the aging process was very rapid. In
addition, studies in cancer cells have revealed the involvement
of the histone deacetylase 5 (HDAC5) in maintaining telo-
mere length. Novo et al. (2013) reported significant telomere
shortening in osteosarcoma and fibrosarcoma cells with no
HDAC5 activity. In fibrosarcoma cells, they also observed a
higher recombination potential of telomeres. These studies
also demonstrated a higher sensitivity to chemotherapy in
cancer cells lacking HDAC5 activity (Novo et al. 2013). The
telomeric sequences form G4 structures (G-quadruplex) that
may cause delay of the replication process and genomic
instability (Lin et al. 2013). These structures are recognized
and cut by DNA2 helicase/nuclease and results in telomere
stabilization (Lin et al. 2013). Some studies indicate an im-
portant role of flap endonuclease 1 (FEN1) in maintaining
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genome stability through its participation in the replication
process. Telomeres in cells lacking FEN1 activity show insta-
bility and dysfunction (Saharia et al. 2008, 2010).
Other proteins interacting with telomeres include tankyrase
1 and tankyrase 2, poly(ADP-ribose) polymerase 1 and 2
(PARP1/2), DNA-PK (DNA-dependent protein kinase),
Ku70/80, MRN complex, ATM (ataxia telangiectasia mutat-
ed), MRE11, WRN (Werner’s syndrome protein), BLM
(Bloom’s syndrome protein), DNA repair protein RAD51D,
and others (Bailey and Murnane 2006; Verdun and Karlseder
2007).
With each replication cycle, telomeres gradually lose 50 to
150 bp, which is a natural process related to the telomere’s
structure and DNA replication mechanism (Harley et al. 1990;
Counter et al. 1992). Telomere shortening may be induced and
accelerated by oxidative stress and DNA damage. Reaching
the critical threshold of telomeres (Hayflick limit) leads to
cellular senescence and, eventually, cell death (Gilley et al.
2008). Telomere dysfunction and shortening are linked to
mitochondrial biology through the activation of P53, which
affects the functioning of PGC-1α and PGC-1β, resulting in a
decrease of mitochondrial mass and energy production (Sahin
et al. 2011).
Techniques utilized in telomere length measurements
Techniques used in the measurement of telomeres can be
divided into two groups. The first group consists of molecular
techniques and include techniques such as TRF (terminal
restriction fragmentation), qPCR (quantitative polymerase
chain reaction), MMqPCR (monochrome multiplex quantita-
tive PCR), aTLqPCR (absolute telomere length quantitation),
and STELA (single telomere length analysis). The second
group consists of cytogenetic techniques based on fluores-
cence in situ hybridization (FISH), such as Q-FISH, PRINS,
Flow-FISH, and HT Q-FISH. Various techniques and their
advantages and disadvantages have been widely described by
Montpetit et al. (2014). Briefly, most of the cytogenetic tech-
niques are suitable for chromosome-specific analysis in small
groups of individuals; they require more time compared to
qPCR-based methods and more sophisticated equipment, like
fluorescent or confocal microscopes. The molecular method
TRF is considered the gold standard in the analysis of the
mean telomere length; however, it is not designed for large
groups of individuals. For such groups, more efficient are
qPCR-based methods, such as qPCR, MMqPCR, and
aTLqPCR. STELA allows for the measurement of critically
short telomeres in a small set of chromosomes (Xp, Xq, 2p,
11q, 12q, and 17p). The Universal STELA method was de-
veloped to identify any short telomeres in the analyzed
material.
Telomere length and osteoarthritis
Telomere shortening is involved in the pathogenesis of age-
related diseases, among which osteoarthritis is one of the most
common. Martin and Buckwalter (2001) conducted studies on a
group of 27 patients, who were aged 1–87 years, and showed
that age-related changes in human cartilage chondrocytes may
lead to cartilage erosion and osteoarthritis. They also demon-
strated that chondrocytes are devoid of telomerase activity
(Martin and Buckwalter 2001). To assess the degree of telomere
erosion, they utilized Southern blot analysis, bywhich they could
estimate the mean terminal restriction fragment length (MTL).
The results showed a significant difference in the MTL value
between the young patients (11.8 kbp for a 13-year-old individ-
ual) and the old patients (8.7 kbp for an 87-year-old individual)
(Martin and Buckwalter 2001). Price et al. (2002) used the same
method to estimate telomere length in osteoarthritis patients and
reported that chondrocytes obtained from the affected sites of
osteoarthritis cartilage have shorter telomeres compared to unaf-
fected chondrocytes. This research was carried out on an age-
homogeneous group of 15 patients with hip osteoarthritis and 30
patients with knee osteoarthritis; the control group consisted of
11 patients with no joint diseases. Zhai et al. (2006)measured the
relative telomere length in leukocytes of 1,086 patients (160
patients with hand osteoarthritis and 926 patients without hand
osteoarthritis), and found that the telomeres of affected patients
were shorter by 178 bp compared to the unaffected group. These
results may indicate that leukocyte telomere length is a biomark-
er of osteoarthritis (Zhai et al. 2006; Li et al. 2012a, b). Telomere
shortening in leukocytes in the course of osteoarthritis is most
likely associated with exposure to oxidative stress and inflam-
matory states ongoing within the affected joints (Fig. 1). These
factors can accelerate DNA replication, causing telomere loss
(Zhai et al. 2006). In vitro studies of human chondrocytes
showed the effects of oxidative stress on cellular aging, telomere
instability, and erosion (Martin et al. 2004; Yudoh et al. 2005).
Tamayo et al. (2010) studied telomere length in peripheral blood
leukocytes of patients with rheumatologic diseases and osteoar-
thritis. An average telomere length wasmeasured via qPCR. The
analyzed group consisted of 34 patients with osteoarthritis and
130 controls; however, there was no difference in the telomere
length between these two groups (Tamayo et al. 2010). In 2011,
Tamayo et al. compared the telomere length of human
chondrocytes and peripheral blood leukocytes. In this study, they
analyzed a group of 20 control subjects and 39 osteoarthritis
patients, consisting of 25 patients with knee osteoarthritis and 14
with hip osteoarthritis (Tamayo et al. 2011). In osteoarthritis
patients, telomeres were 1.6 times longer in chondrocytes com-
pared to leukocytes. In the control subjects, telomeres in
chondrocytes were even twice as long as telomeres from leuko-
cytes. The percentage of numerical chromosomal aberrations in
chondrocytes from osteoarthritis patients was 1.5 times higher
compared to leukocytes and 1.7 times higher than in
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chondrocytes from unaffected controls. No difference was
detected between the leukocytes and chondrocytes of controls.
Increased numerical chromosomal aberrations in the
chondrocytes and leukocytes of osteoarthritis patients indicate
that cells show signs of genomic instability, which is not
limited to the affected joint. Shorter telomeres in leukocytes
may result most likely from frequent divisions of leukocytes
compared to chondrocytes (Tamayo et al. 2011). Rose et al.
(2012) conducted a study on osteoarthritis cartilage collected
during joint replacement from femoral condyles and compared
it with cartilage collected during autopsies. The senescent
phenotype was observed in chondrocytes affected by
osteoarthritis; however, significant telomere shortening was
not detected. This study showed a chaotic gene expression
Fig. 1 Aging and genetic factors contribute to the development of osteoarthritis, which is characterized by accelerated senescence, telomere shortening,
changes in the structure of cartilage, and function of chondrocytes
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pattern and a significant increase in DNA damage in
osteoarthritis chondrocytes compared to unaffected
chondrocytes. In 2012, Harbo et al. (2012) collected tibia pla-
teaus from three postmenopausal women at the ages of 56, 62,
and 67 years. The telomere length was analyzed in cells from
two sites differing in distance from the central osteoarthritic
lesion. Quantification of ultrashort telomeres was performed
via Universal STELA, and the mean telomere length was esti-
mated with Q-FISH (Harbo et al. 2012). This study revealed that
the distance from the center of the osteoarthritic lesion site is
associated with telomere length just as a level of senescence and
a level of osteoarthritis progression. In 2013, Harbo et al. ana-
lyzed tissue from the femoral heads of 14 osteoarthritis patients at
the age of 60–86 years and nine patients without osteoarthritis at
the age of 62–86 years. They revealed a correlation between the
presence of ultrashort telomeres and distance from the central
weight-bearing area of the joint in affected and unaffected indi-
viduals. In addition, the mean telomere length correlated with
distance from the central weight-bearing area, except in the most
central zone, where cells with longer telomeres were detected.
Immunohistochemical analysis revealed that these are
progenitor-like cells, which are most likely recruited to the
degradated area of the joint (Harbo et al. 2013). Sibille et al.
(2012) compared two groups of 18 individuals; the first group
was affected by chronic stress and chronic pain caused by knee
osteoarthritis, and the other group was a control group. They
measured the telomere length in peripheral blood leukocytes
using the qPCR method, described by Cawthon (2002), and
found that telomeres were significantly shorter in patients from
the affected group compared to healthy controls (Sibille et al.
2012). Most of these studies were conducted on small groups of
patients, but they make important contributions to the under-
standing of the cellular senescence that occurs in cartilage tissue.
Telomere shortening in other disorders
Telomere length may be associated with other diseases, such
as cardiovascular disease, dementia, diabetes, cognitive de-
cline, dyskeratosis congenita, aplastic and Fanconi anemia,
idiopathic pulmonary fibrosis, cancer, and more (Martin-Ruiz
et al. 2006; Fitzpatrick et al. 2011; Nilsson et al. 2013; Kong
et al. 2013). Numerous studies indicate a link between telo-
mere length in peripheral blood leukocytes and diseases
unrelated to the hematopoietic system. Yan et al. (2011) re-
ported that short telomeres in leukocyte are associated with
aortic dissection. They studied white blood cells’ telomeres in
72 patients with aortic dissection, compared them to the
telomeres of 72 health controls with no vascular disease,
and, using qPCR, found that telomeres in leukocytes of pa-
tients with aortic dissection were significantly shorter than in
the control group (Yan et al. 2011). These results are consis-
tent with earlier findings. Wilson et al. (2008) carried out
research on a group of 20 patients with asymptomatic abdom-
inal aortic aneurysm (AAA) and on a control group consisting
of 12 cadaveric organ donors. In both groups, they analyzed
telomere length in the aortic biopsy as well as in the leuko-
cytes, and found that the content of leukocyte and aortic
telomere DNA was significantly lower in the patients with
AAA compared to the control group (Wilson et al. 2008).
Many researchers observed telomere shortening in leukocytes
in other cardiovascular diseases, such as atherosclerosis
(Samani et al. 2001) or large artery stiffness and cardiovascu-
lar burden (Wang et al. 2011). Sampson et al. (2006) reported
that monocyte telomeres obtained from the blood of diabetic
patients were shorter compared to the telomeres of the control
group. Leukocyte telomeres showed no significant differences
between the two groups, which may indicate that monocyte
precursor cells could be exposed to high oxidative stress
(Sampson et al. 2006). Honig et al. (2012) showed that short
leukocyte telomeres are associated with dementia and mortal-
ity; the studied group consisted of 1,983 patients aged 65 years
or older. Leukocyte telomere shortening was also observed in
chronic obstructive pulmonary disease (COPD), which is
supposed to be an age-related disease (Savale et al. 2009).
Savale et al. (2009) compared three groups of patients: the first
group was affected by COPD, the second group consisted of
smokers, and third group with no respiratory diseases. They
found that the leukocyte telomeres of COPD patients were
significantly shorter than in the other two groups (Savale et al.
2009). Leukocyte telomere shortening is also observed in viral
infections, such as hepatitis C. Kitay-Cohen et al. (2008)
compared groups of chronic hepatitis C virus (HCV)-infected
patients with patients after remission and a healthy control
group. They showed that patients with chronic HCV infection
had shorter telomeres than the healthy group. These studies
show that telomere length in peripheral blood leukocytes can
be a prognostic factor for other tissues.
In 2007, Njajou et al. (2007) studied telomere length in a
large Amish group including 356 men and 551 women. They
found telomere length to be negatively correlated with age and
positively correlated with lifespan; their analysis also showed
no significant differences in telomere length between men and
women (Njajou et al. 2007). A very important point in this
study was to show that offspring telomere length is correlated
with paternal telomere length (Njajou et al. 2007). Eisenberg
et al. (2012) demonstrated that offspring telomere length is
dependent on the paternal age. Telomerase, functioning in the
sperm, lengthens telomeres and are inherited by the offspring
(Eisenberg et al. 2012). The most recent studies show that
lifestyle and diet may affect the telomere length. Ornish et al.
(2013) conducted a long-term study on two groups of men, ten
men in the “lifestyle intervention group” and 25 men in the
control group. Patients from the first group underwent lifestyle
changes involving diet and activity (Ornish et al. 2013). After
five years, the telomere length was estimated using qPCR.
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These analyses showed significant telomere shortening in the
control group and increase of telomere length in the “lifestyle
intervention group” (Ornish et al. 2013).
Conclusions
Telomere shortening is a natural process that occurs in somatic
cells, but accelerated shortening is observed in many diseases.
Osteoarthritis is a condition in which, in addition to age,
genetic, and environmental factors, telomere shortening may
play a significant role (Fig. 1). Current research shows that
measurements of telomere length in chondrocytes may be a
valuable marker in the evaluation of cellular aging and pre-
diction of osteoarthritis progression.
It seems that the most appropriate approach to measure
telomere shortening is based on the comparison of samples
collected from the same tissue (e.g., cartilage collected from
more and less severely affected parts of the joint). This ap-
proach eliminates errors due to variation in telomere length
between different individuals at birth. Unfortunately, this error
is not eliminated while comparing different groups of individ-
uals (e.g., cartilage collected from patients with osteoarthritis
and unaffected controls). The mean telomere length seems to
be a stable indicator of telomere length; however, it does not
provide information about critically short telomeres, which is
obtained via measurements with the Universal single telomere
length analysis (STELA) method.
Currently, the diagnosis of osteoarthritis is mainly based on
radiographic studies, which detect late stages of this disorder.
A better understanding of molecular mechanisms involved in
the initiation and progression of osteoarthritis may show new
directions in the early diagnosis and new treatment methods of
this extremely common population disorder. The identifica-
tion of novel early biomarkers for osteoarthritis may allow to
slow down osteoarthritis progression and help predict out-
comes of osteoarthritis in individual patients. Telomere length
and telomere shortening in leukocytes and chondrocytes could
become early biomarkers for osteoarthritis; however, to make
final conclusions, the analysis of larger and more homogenous
groups needs to be performed. Thus far, most of the telomere
studies were conducted on small groups of patients, frequently
with knee or hip osteoarthritis combined into one group. In
addition, more studies should be performed in order to better
understand the effect of telomere shortening on cartilage
aging.
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